

CITATION REPORT

List of articles citing

Investigational drug therapies currently in early-stage clinical development for the treatment of clostridioides (clostridium) difficile infection

DOI: 10.1080/13543784.2019.1581763

Expert Opinion on Investigational Drugs, 2019, 28, 323-335.

Source: <https://exaly.com/paper-pdf/73776670/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
5	Discovery and development of DNA polymerase III C inhibitors to treat Gram-positive infections. <i>Bioorganic and Medicinal Chemistry</i> , 2019 , 27, 3209-3217	3.4	15
4	Investigational Treatment Agents for Recurrent Infection (rCDI). <i>Journal of Experimental Pharmacology</i> , 2020 , 12, 371-384	3	4
3	A contemporary review of <i>Clostridioides difficile</i> infections in patients with haematologic diseases. <i>Journal of Internal Medicine</i> , 2021 , 289, 293-308	10.8	3
2	The small acid-soluble proteins of <i>Clostridioides difficile</i> are important for UV resistance and serve as a check point for sporulation.		
1	The small acid-soluble proteins of <i>Clostridioides difficile</i> are important for UV resistance and serve as a check point for sporulation. <i>PLoS Pathogens</i> , 2021 , 17, e1009516	7.6	0